Transcription of ZOLEDRONIC ACID (ZOMETA & RECLAST - UHCprovider.com …
{{id}} {{{paragraph}}}
Example: bankruptcy
ZOLEDRONIC ACID (ZOMETA & RECLAST - UHCprovider.com …
ZOLEDRONIC acid (Zometa & RECLAST ) Page 1 of 4 UnitedHealthcare Medicare Advantage Policy Guideline Approved 08/12/2020 Proprietary Information of UnitedHealthcare. Copyright 2020 United HealthCare Services, Inc. ZOLEDRONIC acid (ZOMETA & RECLAST ) Guideline Number: Approval Date: August 12, 2020 Table of Contents Page POLICY SUMMARY .. 1 APPLICABLE CODES .. 2 PURPOSE .. 2 REFERENCES .. 3 GUIDELINE HISTORY/REVISION INFORMATION .. 3 TERMS AND CONDITIONS .. 3 POLICY SUMMARY Overview ZOLEDRONIC acid ( RECLAST and Zometa) is a bisphosphonic acid , which is an inhibitor of osteoclastic bone resorption. ZOLEDRONIC acid binds to the bone matrix, which decreases osteoclastic activity, prevents bone resorption and skeletal calcium release induced by various stimulatory factors released by tumors. ZOLEDRONIC acid is currently available under the brand names Zometa and RECLAST .
Zoledronic Acid (Zometa ® & Reclast ®) Page 2 of 4 UnitedHealthcare Medicare Advantage Policy Guideline Approved 08/08/2018 . Proprietary Information of UnitedHealthcare.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: